Page 189 - 2021_06-Haematologica-web

B-cell content in advanced-stage cHL
A
Figure 4. Overall survival according to CD20 content. (A) Kaplan-Meier plots of over- all survival in the study cohort for the two risk groups accord- ing to B-cell content (CD20- positive cell rate: ≤21% or >21%). (B) Kaplan-Meier plots of overall survival in the vali- dation cohort for the two risk groups according to B-cell con- tent (CD20-positive cell rate: ≤10% or >10%).
B
a robust discrimination of patients at high risk of experi- encing relapse or progressive disease and thus identifies a population of patients who may qualify for novel first-line treatment strategies. Furthermore, we envision that WSI may also be applied to identify patients in whom de-esca- lation of treatment intensity may be possible. We thus anticipate the use of WSI in all future GHSG studies. Even though additional testing is required to define cut-off val- ues, this approach is close to clinical application since the data required (CD20 staining) are generated in the stan- dard diagnostic workup of any cHL around the world. We cannot imagine any other technology with such a broad potential for application, considering that even in less well-developed countries access may be affordable.
Finally, this is a unique opportunity to establish a risk model looking specifically at the microenvironment in prospective clinical trials.
Disclosures
AE: consultancy or advisory services for and honoraria from Takeda and BMS; research funding from Takeda, BMS and Affimed; honoraria. HCR: consultancy or advisory services for Abbvie and AstraZeneca; research funding from Gilead Sciences. BvT: consultancy or advisory services for Amgen, Pfizer, Takeda and MSD; honoraria from Roche, Takeda and MSD; research funding from Novartis, MSD and Takeda. WK: consultancy or advisory services for and honoraria from Takeda; research fund- ing from Takeda, Amgen, Regeneron and Roche.
haematologica | 2021; 106(6)
1691